Financial Performance - Klotho Neurosciences, Inc. reported no revenue for the three months ended March 31, 2025 and 2024 [112]. - The net loss for the three months ended March 31, 2025 was $2,233,982, compared to a net loss of $672,044 for the same period in 2024, indicating a significant increase in losses [114]. Operating Expenses - Operating expenses increased to $1,586,968 for the three months ended March 31, 2025, up from $672,045 in the same period in 2024, representing an increase of approximately 136% [113]. Cash Flow - Net cash used in operating activities rose to $1,553,747 for the three months ended March 31, 2025, compared to $21,976 for the same period in 2024, an increase of approximately 6,000% [116]. - Cash at the end of the year was $565,869 as of March 31, 2025, compared to $32,336 at the end of the previous year [115]. - Net cash provided by financing activities was $2,055,875 for the three months ended March 31, 2025, an increase of approximately 1,070% compared to $175,000 in the same period in 2024 [118]. Accumulated Deficit - The company has an accumulated deficit of approximately $12.8 million as of March 31, 2025 [120]. Business Operations - The company expects to continue incurring significant professional costs to remain publicly traded and has incurred significant transaction costs related to the business combination [119]. - Klotho Neurosciences, Inc. is classified as an "emerging growth company" and intends to take advantage of certain exemptions from reporting requirements [122]. - The company has no off-balance sheet arrangements as of March 31, 2025 [121].
Klotho Neurosciences, Inc.(KLTO) - 2025 Q1 - Quarterly Report